A model using concomitant markers for predicting outcome in human papillomavirus positive oropharyngeal cancer
| Autor: | Torbjörn Ramqvist, Nikolaos Tertipis, Andrea Vlastos, Eva Munck-Wikland, Anders Näsman, Tina Dalianis, Lars Sivars, Nathalie Grün, Linnea Haeggblom, Cinzia Bersani, Andreas Ährlund-Richter, Michael Mints, Cecilia Smedberg |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Human Papillomavirus Positive Oncology Adult Male Cancer Research medicine.medical_specialty Cancer therapy Human leukocyte antigen law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Internal medicine medicine Humans Survival analysis Aged Aged 80 and over business.industry Papillomavirus Infections Cancer Middle Aged medicine.disease Survival Analysis Surgery Oropharyngeal Neoplasms Tumor Virus Infections 030104 developmental biology Treatment Outcome 030220 oncology & carcinogenesis Concomitant Carcinoma Squamous Cell Female Oral Surgery business CD8 Biomarkers |
| Zdroj: | Oral oncology. 68 |
| ISSN: | 1879-0593 |
| Popis: | Objective Head-neck cancer therapy has become intensified. With radiotherapy alone, 3-year disease-free survival (DFS) is 80% for HPV-positive TSCC/BOTSCC and better for patients with favorable characteristics, suggesting therapy could be tapered for some, decreasing side-effects. Therefore, we built a model to predict progression-free survival for patients with HPV-positive TSCC and BOTSCC. Material and methods TSCC/BOTSCC patients treated curatively between 2000 and 2011, with HPV16 DNA/E7 mRNA positive tumors examined for CD8 + TILs, HPV16 mRNA and HLA class I expression were included. Patients were split randomly 65/35 into training and validation sets, and LASSO regression was used to select a model in the training set, the performance of which was evaluated in the validation set. Results 258 patients with HPV DNA/E7 mRNA positive tumors could be included, 168 and 90 patients in the respective sets. No treatment improved prognosis compared to radiotherapy alone. CD8 + TIL counts and young age were the strongest predictors of survival, followed by T-stage Conclusion CD8 + TIL counts, age, T-stage and E2 expression could predict progression-free survival, identifying patients eligible for randomized trials with milder treatment, potentially reducing side effects without worsening prognosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect